R-Biopharm said on Tuesday that it has acquired AusDiagnostics, an Australian maker of multiplexing molecular diagnostic assays and reagents.

The US Food and Drug Administration last week granted DxLab Emergency Use Authorization for its molecular DxLab COVID-19 test.

The Construction of Mindray, Biotime and Nanomicro R&D Bases Begins

Recently, Fosun Pharma is planning to incorporate OncoCare, one of the largest private oncology medical centers in Singapore.

By the year 2030, pancreatic cancer is expected to become the second most common cause of cancer deaths for both men and women in the United States, according to recent reports. While considered uncommon, inherited gene mutations can increase a person’s risk of developing pancreatic cancer.

Pfizer Inc. announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment.

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a broad strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca’s therapies.

The US Food and Drug Administration this week granted Emergency Use Authorization for LG Chem's AdvanSure SARS-CoV-2 IgG(RBD) ELISA COVID-19 antibody test.

Thermo Fisher Scientific and Qatar Genome Program, a member of the Qatar Foundation, have announced a partnership to use custom genotyping arrays to accelerate genomic research and the clinical applications of predictive genomics in Qatar.

Suzhou Bangqi Biotechnology Co., Ltd.（translated from company’s Chinese name） completed tens of millions of yuan in Series A financing, laying out the field of self-free & allergy diagnosis

The Food and Drug Administration’s Center for Devices and Radiological Health plans to start accepting pre-submission requests for in vitro diagnostics starting on June 1, including for tests not related to COVID-19.

A study of 1.3 million women in England has provided evidence to support the extension of cervical cancer screening intervals from three years to five years for those that have a negative screen result.

This is the 68th edition of our annual ranking of America’s largest companies, and it was a blowout year for the companies featured—despite rising inflation, the ongoing supply chain crisis, and the second year of the COVID-19 pandemic.

Cardiff site will manufacture single-use bioprocessing technologies used to make vaccines and biopharmaceuticals for global customers.

Chinese precision oncology firm Burning Rock Biotech reported on Tuesday that its first quarter 2022 revenues were up 27 percent year over year.